Antibodies News and Research

RSS

Experimental, genetically attenuated malaria vaccine warrants further exploration

Findings from a preliminary human study of an experimental, genetically attenuated malaria parasite immunization show this vaccine warrants further exploration.

24 Aug 2022

Vertical transfer of humoral immune protection after maternal SARS-CoV-2 vaccination

In a new study, researchers assessed the presence, durability, and neutralization potency of immunoglobulin G and IgA antibodies against SARS-CoV-2 in breastfeeding infant stools, maternal plasma, and breast milk following maternal COVID-19 vaccination.

24 Aug 2022

Researchers identify a potential new therapeutic approach to fight angioimmunoblastic T-cell lymphoma

A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop.

24 Aug 2022

The safety, tolerability, and pharmacokinetics of a muco-trapping monoclonal antibody delivered by inhalation

Researchers conducted a phase I clinical trial of IN-006, an inhaled monoclonal antibody treatment for COVID-19.

24 Aug 2022

Glucokinase activator AZD1656 shows potential benefit for diabetics with moderate to severe COVID-19

A new study examines the potential benefit of the glucokinase activator molecule AZD1656 in the ARCADIA trial.

23 Aug 2022

Updated guidelines on the Valneva SARS-CoV-2 vaccine

The WHO provides interim guidelines for the use of the Valneva vaccine.

23 Aug 2022

Wyss Institute's DNA nanotechnology-driven SPEAR protein-detection technology licensed to Spear Bio

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Spear Bio, Inc.announced that the Institute's DNA nanotechnology-driven ultrasensitive SPEAR protein-detection technology has been licensed to the newly formed Boston-based startup.

23 Aug 2022

Epistasis leads to the reduction in genetic barrier to COVID-19 neutralizing antibody escape

A new study addresses the important question of how the SARS-CoV-2 virus would evolve in the future to be able to escape diverse and broadly neutralizing antibodies.

23 Aug 2022

DNA origami as an alternative platform to display the RBD of SARS-CoV-2

Researchers demonstrated DNA origami as a potential platform to display the SARS-CoV-2 receptor-binding domain.

23 Aug 2022

What risk factors are associated with post-acute sequelae of SARS-CoV-2?

Researchers explored the risk factors correlated with post-acute sequelae of SARS-CoV-2.

23 Aug 2022

What are the effects of anti-spike antibody levels on SARS-CoV-2 infection risk?

In a new study, researchers investigated the effect of anti-spike antibody levels on the risk of infection with SARS-CoV-2.

23 Aug 2022

The role of SARS-CoV-2 in COVID-19-associated chilblains

A recent study published in the British Journal of Dermatology evaluated COVID-19-associated chilblains.

23 Aug 2022

How effective are nanotechnology-based vaccines, drugs, and antibodies to combat variants of SARS-CoV-2?

Researchers explored how effectively nanotechnology-based novel and potential vaccines, drugs, and monoclonal antibodies could combat the current and yet to emerge SARS-CoV-2 variants.

22 Aug 2022

Study shows rapid waning of immune protection due to prior BA.1/BA.2 infection against BA.5 breakthrough infection

Researchers investigated the waning of protective immunity conferred by prior infection by Omicron sub-variants BA.1, BA.2 towards its most recent sub-variant BA.5.

22 Aug 2022

The effectiveness of three repurposed drugs in preventing serious SARS-CoV-2 infection in non-hospitalized adults

Researchers conducted a phase III clinical trial to test the effectiveness of three repurposed drugs - metformin, ivermectin, and fluvoxamine, in preventing progression to severe COVID-19.

22 Aug 2022

Durability of immune protection after booster immunization with COVID-19 adjuvanted subunit vaccine against the immune-evasive Omicron BA.1 variant

Researchers explored the durability of immunity imparted by the SARS-CoV-2 adjuvanted subunit vaccine against the Omicron variant.

22 Aug 2022

Re-defining the limits of single batch assay stabilisation

In response to increasing demand for stabilised molecular diagnostic assays, we have significantly increased our single batch lyophilised reagent bead manufacturing throughput to 300,000 reactions per freeze drying run and are now progressing towards a capacity of 100 million tests per annum.

From Biofortuna Limited 22 Aug 2022

New discovery helps explain the dynamics underlying liver damage in type 2 diabetes and obesity

When fat accumulates in the liver, the immune system may assault the organ. A new study from Weill Cornell Medicine researchers identifies the molecule that trips these defenses, a discovery that helps to explain the dynamics underlying liver damage that can accompany type 2 diabetes and obesity.

19 Aug 2022

Scientists identify new driver for rare type of liver cancer

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem have identified in mice the cell of origin of combined liver/biliary duct carcinomas, a rare type of cancer of the liver.

19 Aug 2022

SARS-CoV-2 variant neutralization and novel mAbs reveal protection against Omicron in new research

Researchers assessed the SARS-CoV-2 variants of concern (VOCs) transmission dynamics and neutralization by vaccine-induced antibodies and monoclonal antibodies (mAbs).

19 Aug 2022

Antibodies News and Research

Experimental, genetically attenuated malaria vaccine warrants further exploration

Vertical transfer of humoral immune protection after maternal SARS-CoV-2 vaccination

Researchers identify a potential new therapeutic approach to fight angioimmunoblastic T-cell lymphoma

The safety, tolerability, and pharmacokinetics of a muco-trapping monoclonal antibody delivered by inhalation

Glucokinase activator AZD1656 shows potential benefit for diabetics with moderate to severe COVID-19

Updated guidelines on the Valneva SARS-CoV-2 vaccine

Wyss Institute's DNA nanotechnology-driven SPEAR protein-detection technology licensed to Spear Bio

Epistasis leads to the reduction in genetic barrier to COVID-19 neutralizing antibody escape

DNA origami as an alternative platform to display the RBD of SARS-CoV-2

What risk factors are associated with post-acute sequelae of SARS-CoV-2?

What are the effects of anti-spike antibody levels on SARS-CoV-2 infection risk?

The role of SARS-CoV-2 in COVID-19-associated chilblains

How effective are nanotechnology-based vaccines, drugs, and antibodies to combat variants of SARS-CoV-2?

Study shows rapid waning of immune protection due to prior BA.1/BA.2 infection against BA.5 breakthrough infection

The effectiveness of three repurposed drugs in preventing serious SARS-CoV-2 infection in non-hospitalized adults

Durability of immune protection after booster immunization with COVID-19 adjuvanted subunit vaccine against the immune-evasive Omicron BA.1 variant

Re-defining the limits of single batch assay stabilisation

New discovery helps explain the dynamics underlying liver damage in type 2 diabetes and obesity

Scientists identify new driver for rare type of liver cancer

SARS-CoV-2 variant neutralization and novel mAbs reveal protection against Omicron in new research

A new way of characterising biomolecules eBook

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest Life Science News